AVAC Fellow Moses Supercharger has this primer on the upward trend of HIV drug resistance in Uganda, with action items for advocates.
Fighting HIV Drug Resistance in Uganda
PrEP 101 Presentation from US Women & PrEP Working Group
Created by the US Women and PrEP Working Group, this PowerPoint is intended to help make quality, basic presentations on PrEP to community members.
Layers of Biomedical HIV Prevention Trial Stakeholders
Various stakeholders may influence or be affected by a biomedical HIV prevention trial. Stakeholders include trial participants and other community stakeholders as well as a broader range of national and international stakeholders.
Excerpted from the Good Participatory Practice (GPP) Guidelines, which provide trial funders, sponsors, and implementers with systematic guidance on how to effectively engage with all stakeholders in the design and conduct of biomedical HIV prevention trials. More at avac.org/gpp.
PrEP for MSM in Africa: Meeting Summary and Next Steps
Advocates gather in South Africa for the continent’s first PrEP and MSM consultation to chart a path for PrEP access. See the report summary with links to presentations and country plans.
Biomedical Prevention in 2016 – At a Glance
A snapshot of prevention strategies underway or under development from 2015-2020. Excerpted from AVAC Report 2016: Big Data, Real People.
Gender Binaries and Competition for Resources
In the past year, as focus has rightly been placed on the needs of adolescent girls and young women, some stakeholders have suggested that men are being left behind. The offers a perfect example of data that prompt counterproductive action. Men aren’t being left behind. Both men and women, and boys and girls, are underserved in different ways.
This graphic was excerpted from AVAC Report 2016: Big Data, Real People.
Key Barriers to Women’s Access to HIV Treatment: Making ‘Fact-Track’ a Reality
It is essential to understand the barriers to and facilitators of women’s access to ART, so that individual choices about when and whether to start, and continue with, treatment translate into positive mental and physical health outcomes for the woman, as well as benefiting public health.
In this review, socio-structural factors were explored at macro-, meso- and micro-levels in order to better understand the experiences women living with HIV have of treatment availability and their decision-making around uptake, and to assess how treatment programmes affect their lives. Removing barriers and changing policies and programmes to align with best practices will contribute substantially to efforts for the achievement of global goals such as the ‘90-90-90’ UNAIDS ‘Fast-Track’ targets.
Second European HIV Prevention Summit Meeting Report
In January 2016, the European AIDS Treatment Group (EATG) and AVAC jointly convened the second European HIV Prevention Summit in Brussels. This meeting brought pharmaceutical companies, public health experts, academics and leading scientists in the field of prevention research together with over 50 European community-based advocates for three days of information exchange and debate. The four-page executive summary is attached. The meeting agenda and slide presentations from the meeting are available for download at http://eatgavacprevention.tumblr.com.
Post IAS 2015 Webinar: What was presented and what it means on the road to Durban 2016
Advocates and researchers discussed data presented at IAS 2015, its implications and what’s next on the road to Durban 2016!
Transgender Women and PrEP: What’s the latest?
The US Women and PrEP Working Group and partners had a first-hand look at PrEP and transgender women — through the eyes of women prescribing it, using it, choosing not to use it, advocates calling for more research on it and policy-makers charged with integrating it into the national HIV response.
You can click here to view the video.
Slides are also available here.